KITE Stock Forecast – Quick Win: 36.83% Return

KITE Stock Forecast

On November 15th 2015, I Know First had published a forecast  showing how KITE stock price had fit in accordance with the algorithm’s prediction and ended up with astonishing gains by increasing 36.83%.

KITE stock forecast

Kite Pharma, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to eradicate cancer cells. The Company does this using its engineered autologous cell therapy (eACT), which is an approach to the treatment of cancer.

Kite has recently announced its new exclusive license with the National Institute of Health (NIH) for TCR-based product candidates targeting the MAGE antigens. This is done under the terms of agreement between Kite Pharma and National Cancer Institute.

On November 9th it was also announced that KITE Pharma has started its phase 2 clinical study of KTE-C19 (ZUMA-2) for the treatment of r/r MCL. In other news Kite Pharma has started a research and license agreement with Alpine Immune Sciences to develop protein-based imunotherapies to fight cancer. These developments will help Kite establish a new generation of T-cell therapies. Kite is scheduled to make an upfront payment of $5 million and any additional payments in order to support research.

Before making any trading decisions, consult the latest forecast as the algorithm constantly updates predictions daily. While the algorithm can be used for intra-day trading the predictability tends to become stronger with forecasts over longer time-horizons such as the 1-month, 3-month and 1-year forecasts.

Missed the latest trend? Looking for the next best market opportunity? Find out today’s stock forecast based on our advanced self-learning algorithm